Replicor Announces Initiation of Recruitment for Its Phase IIb Clinical Trial with REP 2139-Mg or REP 2165-Mg in Combination with VireadÂ® and PegasysÂ® or ZadaxinÂ® in Patients with HBeAg Negative Chronic Hepatitis B Infect